| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Emory University School of Medicine, Atlanta, GA 30322.
a Address correspondence to: The Emory Clinic, Inc., 1365 Clifton Rd. NE, Atlanta, GA 30322. Fax 404-778-5230; e-mail nwatts{at}emory.edu
Remodeling is essential for bone health. It begins with resorption of old bone by osteoclasts, followed by the formation of new bone by osteoblasts. Remodeling is coupled (formation is linked to resorption). After middle age or perhaps beginning earlier, bone loss occurs because resorption exceeds formation. This imbalance is accentuated by estrogen deficiency as well as by many diseases and conditions. Biochemical markers that reflect remodeling and can be measured in blood or urine include resorption markers (e.g., collagen cross-links) and formation markers (e.g., alkaline phosphatase).
Bone markers exhibit substantial short-term and long-term fluctuations related to time of day, phase of the menstrual cycle, and season of the year, as well as diet, exercise, and anything else that alters bone remodeling. These biological factors, in addition to assay imprecision, produce significant intra- and interindividual variability in markers.
Bone marker measurements are noninvasive, inexpensive, and can be repeated often. Unfortunately, most of the studies that provided insight on clinical situations did not focus on markers as a primary endpoint. Bone markers have been useful in clinical practice and have been helpful in understanding the pathogenesis of osteoporosis and the mechanism of action of therapies. In clinical trials, markers aid in selecting optimal dose and in understanding the time course of onset and resolution of treatment effect. Clinical questions that might be answered by bone markers include diagnosing osteoporosis, identifying "fast bone losers" and patients at high risk of fracture, selecting the best treatment for osteoporosis, and providing an early indication of the response to treatment. Additional information is needed to define specific situations and cut points to allow marker results to be used with confidence in making decisions about individual patients.© 1999 American Association for Clinical Chemistry
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  M. Ferrone and M. Geraci A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Skulan, T. Bullen, A. D. Anbar, J. E. Puzas, L. Shackelford, A. LeBlanc, and S. M. Smith Natural Calcium Isotopic Composition of Urine as a Marker of Bone Mineral Balance Clin. Chem., June 1, 2007; 53(6): 1155 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Vistoropsky, M. Keter, I. Malkin, S. Trofimov, E. Kobyliansky, and G. Livshits Contribution of the putative genetic factors and ANKH gene polymorphisms to variation of circulating calciotropic molecules, PTH and BGP Hum. Mol. Genet., May 15, 2007; 16(10): 1233 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vehmanen, I. Elomaa, C. Blomqvist, and T. Saarto Tamoxifen Treatment After Adjuvant Chemotherapy Has Opposite Effects on Bone Mineral Density in Premenopausal Patients Depending on Menstrual Status J. Clin. Oncol., February 1, 2006; 24(4): 675 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Fitzgerald, D. J. Hillegonds, D. W. Burton, T. L. Griffin, S. Mullaney, J. S. Vogel, L. J. Deftos, and D. A. Herold 41Ca and Accelerator Mass Spectrometry to Monitor Calcium Metabolism in End Stage Renal Disease Patients Clin. Chem., November 1, 2005; 51(11): 2095 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Voudris, A. Attilakos, E. Katsarou, A. Garoufi, S. Dimou, A. Skardoutsou, and S. Mastroyianni Early Alteration in Bone Metabolism in Epileptic Children Receiving Carbamazepine Monotherapy Owing to the Induction of Hepatic Drug-Metabolizing Enzymes J Child Neurol, June 1, 2005; 20(6): 513 - 516. [Abstract] [PDF]
|
|
|
|
|
|
K. A. Voudris, A. Attilakos, E. Katsarou, A. Garoufi, S. Dimou, A. Skardoutsou, and S. Mastroyianni Early Alteration in Bone Metabolism in Epileptic Children Receiving Carbamazepine Monotherapy Owing to the Induction of Hepatic Drug--Metabolizing Enzymes J Child Neurol, June 1, 2005; 20(6): 513 - 516. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Tanvetyanon Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer J Natl Cancer Inst, January 5, 2005; 97(1): 70 - 70. [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Donahue, M. R. Vaughan, L. M. Demers, and H. J. Donahue Bone formation is not impaired by hibernation (disuse) in black bears Ursus americanus J. Exp. Biol., December 1, 2003; 206(23): 4233 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. C. Kung, H.-T. Chao, K.-E. Huang, A. G. Need, N. Taechakraichana, F.-H. Loh, F. Gonzaga, U. Sriram, N. M. N. Ismail, A. Farooqi, et al. Efficacy and Safety of Raloxifene 60 Milligrams/Day in Postmenopausal Asian Women J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3130 - 3136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. N. Kawahara, D. C. Krueger, J. A. Engelke, J. M. Harke, and N. C. Binkley Short-Term Vitamin A Supplementation Does Not Affect Bone Turnover in Men J. Nutr., June 1, 2002; 132(6): 1169 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J Wenstrup, M Roca-Espiau, N J Weinreb, and B Bembi Skeletal aspects of Gaucher disease: a review Br. J. Radiol., May 24, 2002; 75(90001): A2 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Vesper, L. M. Demers, R. Eastell, P. Garnero, M. Kleerekoper, S. P. Robins, A. K. Srivastava, G. R. Warnick, N. B. Watts, and G. L. Myers Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline Clin. Chem., February 1, 2002; 48(2): 220 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Brown, R. L. Vessella, P. J. Kostenuik, C. R. Dunstan, P. H. Lange, and E. Corey Serum Osteoprotegerin Levels Are Increased in Patients with Advanced Prostate Cancer Clin. Cancer Res., October 1, 2001; 7(10): 2977 - 2983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Okabe, K. Nakatsuka, M. Inaba, T. Miki, H. Naka, H. Masaki, A. Moriguchi, and Y. Nishizawa Clinical Evaluation of the Elecsys {beta}-CrossLaps Serum Assay, a New Assay for Degradation Products of Type I Collagen C-Telopeptides Clin. Chem., August 1, 2001; 47(8): 1410 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-o. Chailurkit, B. Ongphiphadhanakul, N. Piaseu, S. Saetung, and R. Rajatanavin Biochemical Markers of Bone Turnover and Response of Bone Mineral Density to Intervention in Early Postmenopausal Women: An Experience in a Clinical Laboratory Clin. Chem., June 1, 2001; 47(6): 1083 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Berenson, R. A. Vescio, L. S. Rosen, J. M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, et al. A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases Clin. Cancer Res., March 1, 2001; 7(3): 478 - 485. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
